专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR1020120119932A ＰＩ3 키나제 억제제로서 헤테로고리 화합물 无效
标题翻译：杂环化合物作为PI3激酶抑制剂
公开(公告)号：KR1020120119932A
公开(公告)日：2012-11-01
申请号：KR1020110037029
申请日：2011-04-21
申请人： (주)네오팜
发明人： 김태성 , 박부만 , 최형묵 , 이은경 , 전정은
IPC分类号： C07D491/048 , C07D495/04 , A61K31/4355 , A61P37/00
摘要： PURPOSE: A heterocyclic compound and a composition containing the same are provided to control the activation or function of phosphoinositide 3'-OH kinase and to prevent or treat autoimmune and inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, metabolic diseases, respiratory disease or cancer. CONSTITUTION: A heterocyclic compound is denoted by chemical formulas 1-6. A pharmaceutical composition for treating or preventing autoimmune diseases and inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, metabolic diseases, respiratory disease or cancer contains the heterocyclic compounds or pharmaceutically acceptable salt and solvate thereof. A cosmetic composition contains the heterocyclic compounds or pharmaceutically acceptable salts and solvate thereof.
摘要翻译：目的：提供杂环化合物和含有它们的组合物以控制磷酸肌醇3-OH激酶的活化或功能，并预防或治疗自身免疫性和炎性疾病，心血管疾病，神经变性疾病，代谢疾病，呼吸系统疾病或癌症。构成：化学式1-6表示杂环化合物。用于治疗或预防自身免疫疾病和炎性疾病，心血管疾病，神经变性疾病，代谢疾病，呼吸系统疾病或癌症的药物组合物含有杂环化合物或其药学上可接受的盐和溶剂合物。化妆品组合物含有杂环化合物或其药学上可接受的盐和溶剂合物。

2. 发明公开

KR1020120056800A 글루글루카곤 수용체에 대한 항체와 이의 사용 无效
标题翻译：抗胰高血糖素受体的抗体及其用途
公开(公告)号：KR1020120056800A
公开(公告)日：2012-06-04
申请号：KR1020117028123
申请日：2009-09-08
申请人： (주)네오팜
发明人： 이은경 , 김태성 , 서성경
IPC分类号： C07K16/28 , C07K14/46 , C12N5/12 , A61K39/395
CPC分类号： C07K16/2869 , A61K2039/505 , C07K2317/24 , C07K2317/515 , C07K2317/565 , C07K2317/76
摘要： PURPOSE: A composition for reducing glucagon signal transduction activity is provided to suppress the activation of glucagon receptor. CONSTITUTION: An isolated antibody, antigen-binding site, or derivative thereof contains heavy chain CDRs which are successively contained in an amino acid sequence of sequence number 2, 4, 6, 8, 10, 12, 14, or 16; a light chain CDRs which are successively contained in an amino acid sequence of sequence number 18, 20, 22, 24, 26, 28, or 30; or combination thereof. A method of treating, preventing, or suppressing type 2 diabetes, dyslipidemia, or diseases thereof comprises a step of administering a pharmaceutical composition containing the isolated antibody, antigen-binding site or derivative, or antibody.
摘要翻译：目的：提供降低胰高血糖素信号转导活性的组合物，以抑制胰高血糖素受体的活化。构成：分离的抗体，抗原结合位点或其衍生物含有连续包含在序列号2,4,6,8,10,12,14或16的氨基酸序列中的重链CDR; 连续包含在序列号18,20,22,24,26,28或30的氨基酸序列中的轻链CDR; 或其组合。治疗，预防或抑制2型糖尿病，血脂异常或其疾病的方法包括施用含有分离的抗体，抗原结合位点或衍生物或抗体的药物组合物的步骤。

3. 发明授权

KR100961410B1 단백질 키나제 억제제로서 헤테로사이클릭 화합물 有权
标题翻译：杂环化合物作为蛋白激酶抑制剂
公开(公告)号：KR100961410B1
公开(公告)日：2010-06-09
申请号：KR1020090077307
申请日：2009-08-20
申请人： (주)네오팜
发明人： 김태성 , 이은경 , 김도영 , 박부만 , 주정재 , 박지연
IPC分类号： C07D403/08 , C07D231/10 , C07D237/06
CPC分类号： C07D471/04 , C07D487/04
摘要： 본 발명에 의하여, c-Met와 같은 성장 인자 수용체의 단백질 키나제 활성을 억제함으로써 항암제로서 유용하게 사용될 수 있는 신규 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약학적 조성물 및 상기 화합물의 사용 방법이 제공된다. 또한, 본 발명의 상기 화합물을 포함하는 약학적 조성물은 암 이외에, 성장 인자 및 항-혈관형성 수용체, 예컨대 c-Met를 통해 작동하는 신호 전달 경로와 관련된 질환의 치료에 유용하게 사용될 수 있다.
헤테로사이클릭 화합물, 단백질 키나제, 항암제

4. 发明公开

KR1020110130259A ＰＡＲ-2 저해 효능을 갖는 퀴나졸리논 유도체 화합물 및 그 제조방법 无效
标题翻译：具有蛋白激活受体2的抑制活性的喹唑啉酮衍生化合物及其制备方法
公开(公告)号：KR1020110130259A
公开(公告)日：2011-12-05
申请号：KR1020100049817
申请日：2010-05-27
申请人： (주)네오팜
发明人： 곽형섭 , 김용주 , 김욱일 , 김태성 , 박병덕 , 박지연 , 박태교 , 우성호 , 이대연 , 이은경 , 이향숙 , 전정은 , 정세규 , 정은미 , 최형묵
IPC分类号： C07D239/90 , C07D471/04 , A61K31/519 , A61P9/00
摘要： PURPOSE: A novel quinazolinone derivative compound with PAR-2 inhibition is provided to suppress protease-activated receptor-2(PAR-2) and to relieve skin pigmentation, atopic dermatitis, and wound. CONSTITUTION: A quinazolinone derivative compound is denoted by chemical formula 1 or 2. A method for preparing the quinazolinone derivative compounds comprises: a step of reacting a compound of chemical formula 3 with a compound of chemical formula 4 to prepare a compound of chemical formula 5; a step of reacting the compound of chemical formula 5 with hydrazine monohydrate to prepare a compound of chemical formula 6; a step of reacting the compound of chemical formula 6 with a compound of chemical formula 7. A pharmaceutical composition for preventing or treating cardiovascular diseases, gastrointestinal diseases, asthma, pigmentation, atopic dermatitis, and wound contains the quinazolinone derivative compound as an active ingredient.
摘要翻译：目的：提供一种具有PAR-2抑制作用的新型喹唑啉酮衍生物，以抑制蛋白酶活化受体-2（PAR-2），缓解皮肤色素沉着，特应性皮炎和伤口。构成：喹唑啉酮衍生物化合物由化学式1或2表示。制备喹唑啉酮衍生物化合物的方法包括：使化学式3的化合物与化学式4的化合物反应以制备化学式5的化合物 ; 使化学式5的化合物与一水合肼反应以制备化学式6的化合物的步骤; 使化学式6的化合物与化学式7的化合物反应的步骤。用于预防或治疗心血管疾病，胃肠道疾病，哮喘，色素沉着，特应性皮炎和伤口的药物组合物含有喹唑啉酮衍生物化合物作为活性成分。

5. 发明公开

KR1020100051782A 단백질 키나제 억제제로서 헤테로사이클릭 화합물 无效
标题翻译：杂环化合物作为蛋白激酶抑制剂
公开(公告)号：KR1020100051782A
公开(公告)日：2010-05-18
申请号：KR1020100037455
申请日：2010-04-22
申请人： (주)네오팜
发明人： 김태성 , 이은경 , 김도영 , 박부만 , 주정재 , 박지연
IPC分类号： A61K31/41 , C07D403/08 , C07D231/10 , A61P35/00
CPC分类号： C07D471/04 , C07D487/04
摘要： PURPOSE: A new heterocyclic compound and a pharmaceutical composition including thereof are provided to use the compound as an anti-cancer medicine by controlling an activation of a protein kinase of a growth factor receptor including c-Met. CONSTITUTION: A pharmaceutical composition including a new heterocyclic compound contains a protein tyrosine kinase activity inhibition compound to cure cancer, asthma, allergy, atopic dermatitis, inflammation disease, psoriasis or rheumatoid disease. The pharmaceutical composition additionally contains pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier. The heterocyclic compound is marked as chemical formula 1. The pharmaceutical composition is injected to a patient who needs a treatment for the cancer.
摘要翻译：目的：提供一种新的杂环化合物及其包含的药物组合物，以通过控制包括c-Met的生长因子受体的蛋白激酶的活化来使用该化合物作为抗癌药物。构成：包含新的杂环化合物的药物组合物含有蛋白酪氨酸激酶活性抑制化合物，用于治疗癌症，哮喘，过敏，特应性皮炎，炎症疾病，牛皮癣或类风湿病。药物组合物另外含有药学上可接受的盐和药学上可接受的载体。杂环化合物被标记为化学式1.将药物组合物注射到需要治疗癌症的患者中。

6. 发明公开

KR1020100041669A 단백질 키나제 억제제로서 헤테로사이클릭 화합물 有权
标题翻译：杂环化合物作为蛋白激酶抑制剂
公开(公告)号：KR1020100041669A
公开(公告)日：2010-04-22
申请号：KR1020090077307
申请日：2009-08-20
申请人： (주)네오팜
发明人： 김태성 , 이은경 , 김도영 , 박부만 , 주정재 , 박지연
IPC分类号： C07D403/08 , C07D231/10 , C07D237/06
CPC分类号： C07D471/04 , C07D487/04
摘要： PURPOSE: A novel heterocyclic compound is provided to suppress protein kinase activation of growth factor receptor such as c-Met and uses as an anti-cancer drug. CONSTITUTION: A novel heterocyclic compound is denoted by chemical formula 1. A pharmaceutical composition contains therapeutically effective amount of heterocyclic compound. The composition is used in treating HGF-mediated diseases such cancer, asthma, allergic dermatitis, psoriasis, or rheumatic arthritis. The cancer includes non-small cell lung cancer, coloproctitis, glioblastoma, head and neck cancer, stomach cancer, bladder cancer, liver cancer or ovarian cancer. The pharmaceutical composition additionally contains antibiotics, alkylating agent, anti-matabolic agent, immunological formulation, interferon formulation or other anti-cancer formulation.
摘要翻译：目的：提供一种新的杂环化合物来抑制生长因子受体如c-Met的蛋白激酶活化，并用作抗癌药物。构成：化学式1表示新的杂环化合物。药物组合物含有治疗有效量的杂环化合物。该组合物用于治疗HGF介导的疾病如癌症，哮喘，过敏性皮炎，牛皮癣或风湿性关节炎。癌症包括非小细胞肺癌，结肠炎，胶质母细胞瘤，头颈癌，胃癌，膀胱癌，肝癌或卵巢癌。药物组合物另外含有抗生素，烷化剂，抗分解剂，免疫制剂，干扰素制剂或其它抗癌制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式